EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce the company will be presenting four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback